These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7127995)

  • 1. How blind was the patient blind in AMIS?
    Howard J; Whittemore AS; Hoover JJ; Panos M
    Clin Pharmacol Ther; 1982 Nov; 32(5):543-53. PubMed ID: 7127995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How blind is double-blind? A study of fish oil versus placebo.
    Damico KE; Stoll AL; Marangell LB; Cohen BM
    Prostaglandins Leukot Essent Fatty Acids; 2002 Apr; 66(4):393-5. PubMed ID: 12054908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
    Circulation; 1980 Dec; 62(6 Pt 2):V79-84. PubMed ID: 7438383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of double-blindness at the conclusion of the beta-Blocker Heart Attack Trial.
    Byington RP; Curb JD; Mattson ME
    JAMA; 1985 Mar 22-29; 253(12):1733-6. PubMed ID: 3974051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial.
    Popovic M; Cesana-Nigro N; Winzeler B; Thomann R; Schütz P; Müller B; Christ-Crain M; Blum CA
    Swiss Med Wkly; 2019 Jul; 149():w20114. PubMed ID: 31340056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recruitment experience in the Aspirin Myocardial Infarction Study.
    Schoenberger JA
    Control Clin Trials; 1987 Dec; 8(4 Suppl):74S-78S. PubMed ID: 3440392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
    JAMA; 1980 Feb; 243(7):661-9. PubMed ID: 6985998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The double-blind in danger: untoward consequences of informed consent.
    Brownell KD; Stunkard AJ
    Am J Psychiatry; 1982 Nov; 139(11):1487-9. PubMed ID: 6753613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinding, unblinding, and the placebo effect: an analysis of patients' guesses of treatment assignment in a double-blind clinical trial.
    Moscucci M; Byrne L; Weintraub M; Cox C
    Clin Pharmacol Ther; 1987 Mar; 41(3):259-65. PubMed ID: 3816016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participation in a clinical trial: the patients' point of view.
    Mattson ME; Curb JD; McArdle R
    Control Clin Trials; 1985 Jun; 6(2):156-67. PubMed ID: 4006489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapping-in method (skin penetration technique) with a placebo needle for double-blind acupuncture trials.
    Takakura N; Takayama M; Kawase A; Yajima H
    J Altern Complement Med; 2013 Apr; 19(4):308-12. PubMed ID: 23098695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.
    Partridge AH; Sepucha K; O'Neill A; Miller KD; Motley C; Swaby RF; Schneider BP; Dang CT; Northfelt DW; Sledge GW
    JAMA Oncol; 2015 Jun; 1(3):369-74. PubMed ID: 26114161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin in coronary heart disease. The Coronary Drug Project Research Group.
    J Chronic Dis; 1976 Oct; 29(10):625-42. PubMed ID: 789390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double blind: double talk or are there ways to do better research.
    Ney PG; Collins C; Spensor C
    Med Hypotheses; 1986 Oct; 21(2):119-26. PubMed ID: 3641026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational Vertebroplasty Efficacy and Safety Trial: detailed analysis of blinding efficacy.
    Brinjikji W; Comstock BA; Heagerty PJ; Jarvik JG; Kallmes DF
    Radiology; 2010 Oct; 257(1):219-25. PubMed ID: 20851942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic activity after administration of diflunisal and aspirin. A double-blind, randomized, placebo-controlled clinical trial.
    Green D; Davies RO; Holmes GI; Johnson C; Kohl H; Reynolds N; Ts'ao C
    Haemostasis; 1983; 13(6):394-8. PubMed ID: 6365701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
    Wallentin L; Wilcox RG; Weaver WD; Emanuelsson H; Goodvin A; Nyström P; Bylock A;
    Lancet; 2003 Sep; 362(9386):789-97. PubMed ID: 13678873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
    Young FE; Nightingale SL; Temple RA
    JAMA; 1988 Jun; 259(21):3158-60. PubMed ID: 3367492
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain.
    Bergmann JF; Chassany O; Gandiol J; Deblois P; Kanis JA; Segrestaa JM; Caulin C; Dahan R
    Clin Trials Metaanal; 1994 Apr; 29(1):41-7. PubMed ID: 10150184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Behavior of serum triglycerides, cholesterol, uric acid and sugar levels and of thrombocyte function in heart infarct patients during a 2-year therapy with acetylsalicylic acid, placebo or phenprocoumon].
    Weber E; Walter E; Pfleiderer T
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1731-5. PubMed ID: 347797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.